Intranasal delivery of therapeutic proteins for neurological diseases
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Among the range of therapeutic protein candidates for new generation treatments of neurological diseases, neurotrophic factors and recombinant antibodies hold the greatest potential. However, major difficulties in their safe and effective delivery to the brain severely limit these applications. The BBB restricts the exchange of proteins between the plasma and the CNS. Moreover, therapeutic proteins often need to be selectively targeted to the brain, while minimizing their biodistribution to systemic compartments, to avoid peripheral side effects. The intranasal delivery of proteins has recently emerged as a non-invasive, safe and effective method to target proteins to the CNS, bypassing the BBB and minimizing systemic exposure. AREAS COVERED: We critically summarize the main experimental and mechanistic facts about the simple and non-invasive nasal delivery approach, which provides a promising strategy and a potential solution for the severe unmet medical need of safely and effectively delivering protein therapeutics to the brain. EXPERT OPINION: The intranasal route for the effective delivery of recombinant therapeutic proteins represents an emerging and promising non-invasive strategy. Future studies will achieve a detailed understanding of pharmacokinetic and mechanisms of delivery to optimize formulations and fully exploit the nose-to-brain interface in order to deliver proteins for the treatment of neurological diseases. This expanding research area will most likely produce exciting results in the near future towards new therapeutical approaches for the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 8×
“BDNF has also potent neurotrophic survival actions on motoneurons, both in physiological situations and in pathology models, which raised hopes that BDNF could be used for the treatment of neurodegenerative disorders specifically affecting motoneurons, such as ALS [1].”
BackgroundInfluentialProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161 · cited 2×
“As for antibodies, human or humanized antibodies represent the largest class of therapeutic proteins in the pharmaceutical market and the clinical pipelines of the pharmaceutical industry [2,3].”
BackgroundOxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239 · cited 10×
“Several different aspects and parameters for nasal delivery have been analyzed and improved, being the subject of continuing research, and include administration techniques, head position, delivery devices and drop volumes [15].”
BackgroundInfluentialA phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 3×
“In the absence of better ways to bypass the BBB, therapeutics can be introduced directly into the CNS by intracerebroventricular or intraparenchymal injections [1,7].”
BackgroundOxytocin: The Great Facilitator of Life
Lee, H.-J., Macbeth, A. H., Pagani, J., & Young, W. S. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.001 · Cited by 1,037 · cited 1×
“5 Oxytocin: a neuropeptide and a hormone for social binding Oxytocin (OT), a nonapeptide synthesized by specialized cells of the hypotalamus, exerts a dual role in mammalians [105], acting peripherically as a hormone, regulating lactation and parturition, but acting also centrally as neuropeptide, controlling a wide r…”
BackgroundNagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 1×
“The neuroprotective effects of BDNF in different rodent and primate AD models were achieved using the same invasive approaches of gene delivery as for NGF [95].”
MethodThorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Intranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans
Hurlemann, R., Patin, A., Onur, O. A., Cohen, M. X., Baumgartner, T., Metzler, S., Dziobek, I., Gallinat, J., Wagner, M., Maier, W., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5538-09.2010 · Cited by 771
Rennels, M. L., Gregory, T. F., Blaumanis, O. R., Fujimoto, K., & Grady, P. A. (1985) · Brain Research · doi:10.1016/0006-8993(85)91383-6 · Cited by 752 · cited 1×
“This form of ‘perivascular pump’ mechanism, fuelled by the arterial pulsations, could contribute to the observed rapid distribution, throughout the brain, of exogenously applied molecules [51,52].”
BackgroundNanoparticles for direct nose-to-brain delivery of drugs
Mistry, A., Stolnik, S., & Illum, L. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.019 · Cited by 734
Intranasal insulin improves memory in humans
Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H. L., Born, J., & Kern, W. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.04.003 · Cited by 699 · cited 1×
“Using intranasal delivery, it was also found that insulin significantly improved memory and mood in normal individuals [124] without altering blood insulin or glucose levels.”
BackgroundOxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., & Mosovich, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300021 · Cited by 689 · cited 1×
“Currently, intranasal administration of OT in clinical populations has been reported to improve emotion recognition in autism or Asperger’s syndrome, and ameliorate symptoms in schizophrenia, post-traumatic stress disorders and sexual dysfunction [105,111-114].”
BackgroundIntranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease
Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596
The Peptide That Binds: A Systematic Review of Oxytocin and its Prosocial Effects in Humans
MacDonald, K., & MacDonald, T. M. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673220903523615 · Cited by 585 · cited 4×
“5 Oxytocin: a neuropeptide and a hormone for social binding Oxytocin (OT), a nonapeptide synthesized by specialized cells of the hypotalamus, exerts a dual role in mammalians [105], acting peripherically as a hormone, regulating lactation and parturition, but acting also centrally as neuropeptide, controlling a wide r…”
BackgroundInfluentialZlokovic, B. V., Martel, C. L., Matsubara, E., McComb, J. G., Zheng, G., McCluskey, R. T., Frangione, B., & Ghiso, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4229 · Cited by 430
Balin, B. J., Broadwell, R. D., Salcman, M., & El‐Kalliny, M. (1986) · Journal of Comparative Neurology · doi:10.1002/cne.902510209 · Cited by 358
Quantitative analysis of the olfactory pathway for drug delivery to the brain
Thorne, R. G., Emory, C. R., Ala, T. A., & Frey, W. H. (1995) · Brain Research · doi:10.1016/0006-8993(95)00637-6 · Cited by 352 · cited 1×
“Intranasal delivery of proteins [8] has recently emerged as a non-invasive, safe and effective method to target peptide and proteins to the CNS, bypassing the BBB and minimizing systemic exposure.”
MethodCan Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351
Thoenen, H., & Sendtner, M. (2002) · Nature Neuroscience · doi:10.1038/nn938 · Cited by 336 · cited 11×
“BDNF has also potent neurotrophic survival actions on motoneurons, both in physiological situations and in pathology models, which raised hopes that BDNF could be used for the treatment of neurodegenerative disorders specifically affecting motoneurons, such as ALS [1].”
BackgroundInfluentialDrainage of cerebral interstitial fluid into deep cervical lymph of the rabbit
Bradbury, M. W., Cserr, H. F., & Westrop, R. J. (1981) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1981.240.4.f329 · Cited by 335
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients
Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., Minassian, A., Becker, O., Cooper, J., Perry, W., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.039 · Cited by 308
Axonal damage markers in cerebrospinal fluid are increased in ALS
Brettschneider, J., Petzold, A., Süßmuth, S. D., Ludolph, A. C., & Tumani, H. (2006) · Neurology · doi:10.1212/01.wnl.0000203120.85850.54 · Cited by 261 · cited 6×
“BDNF has also potent neurotrophic survival actions on motoneurons, both in physiological situations and in pathology models, which raised hopes that BDNF could be used for the treatment of neurodegenerative disorders specifically affecting motoneurons, such as ALS [1].”
BackgroundInfluentialIgG Reactivity in the Spinal Cord and Motor Cortex in Amyotrophic Lateral Sclerosis
Engelhardt, J. I., & Appel, S. H. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530110068019 · Cited by 221
Perivascular spaces in the basal ganglia of the human brain: their relationship to lacunes
POLLOCK, H., HUTCHINGS, M., WELLER, R. O., & ZHANG, E. (1997) · Journal of Anatomy · doi:10.1046/j.1469-7580.1997.19130337.x · Cited by 220 · cited 2×
“junctions between cells of the olfactory epithelium, made leaky as ORNs turn over and regenerate [35-37], after which they get transported by bulk flow mechanisms within perineural channels formed by olfactory ensheathing glial cells around the olfactory axon bundles.”
BackgroundQuirin, M., Kuhl, J., & Düsing, R. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.12.005 · Cited by 204
Clearance of amyloid β-peptide from brain: transport or metabolism?
Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., & Frangione, B. (2000) · Nature Medicine · doi:10.1038/77397 · Cited by 186
Garcia, P., Youssef, I., Utvik, J. K., Florent-Béchard, S., Barthélémy, V., Malaplate-Armand, C., Kriem, B., Stenger, C., Koziel, V., Olivier, J.-L., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4182-09.2010 · Cited by 139 · cited 1×
“CNTF effectively rescues learning and memory impairments in AD and HD models [97,98], and was even tested in human clinical trials for ALS, with a systemic or an intraventricular delivery [1].”
Pulford, B., Reim, N., Bell, A., Veatch, J., Forster, G., Bender, H., Meyerett, C., Hafeman, S., Michel, B., Johnson, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011085 · Cited by 85
Cited by
Nasal drug delivery — Recent developments and future prospects
Illum, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.024 · Cited by 287
Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles
Ahmad, E., Feng, Y., Qi, J., Fan, W., Ma, Y., He, H., Xia, F., Dong, X., Zhao, W., Lu, Y., et al. (2017) · Nanoscale · doi:10.1039/c6nr07581a · Cited by 194
Nose-to-brain peptide delivery – The potential of nanotechnology
Samaridou, E., & Alonso, M. J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.001 · Cited by 178
Herradón, G., & Pérez‐García, C. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12312 · Cited by 88
Khatri, D. K., Preeti, K., Tonape, S., Bhattacharjee, S., Patel, M., Shah, S., Singh, P. K., Srivastava, S., Gugulothu, D., Vora, L., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x20666220507022701 · Cited by 75
Metadata
- Authors
- Malerba, F., Paoletti, F., Capsoni, S., & Cattaneo, A.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2011-05-27
- Volume
- 8
- Issue
- 10
- Pages
- 1277-1296
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W1971572104
- Cited by
- 73
- References
- 33
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.